Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112733095 | 11273309 | 5 | F | 20141028 | 20160627 | 20150715 | 20160708 | PER | PHHY2015US003061 | NOVARTIS | 20.29 | YR | F | Y | 0.00000 | 20160708 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112733095 | 11273309 | 1 | PS | GILENYA | FINGOLIMOD HYDROCHLORIDE | 1 | Oral | UNK | 22527 | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 112733095 | 11273309 | 1 | Multiple sclerosis |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 112733095 | 11273309 | Anxiety | |
| 112733095 | 11273309 | Benign neoplasm of skin | |
| 112733095 | 11273309 | Blood alkaline phosphatase increased | |
| 112733095 | 11273309 | Constipation | |
| 112733095 | 11273309 | Contusion | |
| 112733095 | 11273309 | Headache | |
| 112733095 | 11273309 | Lymphocyte count decreased | |
| 112733095 | 11273309 | Procedural pain | |
| 112733095 | 11273309 | Seborrhoeic keratosis | |
| 112733095 | 11273309 | Upper respiratory tract infection | |
| 112733095 | 11273309 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |